. Author manuscript; available in PMC: 2014 Oct 1.

Published in final edited form as: Surg Oncol Clin N Am. 2013 Jul 24;22(4):805–821. doi: 10.1016/j.soc.2013.06.001

Table 2.

Tyrosine kinase mutations and targeted agents in solid tumors.

Gene	Tumor	Agent
KIT	Melanoma, seminoma, small cell lung cancer, synovial sarcoma, thymic carcinoma	Imatinib^81–89
PDGFRA	Dermatofibrosarcoma protuberans	Imatinib^90,91
EGFR	Non-small cell lung cancer	Gefitinib, Erlotinib^92–96
	Squamous cell, ovarian, renal cell, and colorectal cancer, glioblastoma multiforme	Erlotinib⁹⁷, gefitinib⁹⁸, Lapatanib⁹⁹, Cetuximab¹⁰⁰ Panitumumab¹⁰¹
BRAF	Melanoma, papillary thyroid cancer, colon cancer	Vemurafenib^102,103
HER-2	Breast cancer, lung cancer	Trastuzumab^104,105
VEGFR	Non-small cell lung, breast, prostate, renal, colorectal	Bevacizumab, VEGF inhibitors¹⁰⁶
RET	Multiple endocrine neoplasia 2A, 2B, Familial Medullary Thyroid Cancer, Radiation-associated papillary thyroid cancer	Cabozantinib¹⁰⁷, Vandetanib¹⁰⁸, Sorafenib¹⁰⁹